Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Treasury Secretary’s Latest Statement: No Need to Worry About the Deadline for the US-China Suspension of Some Tariff Increases, Negotiations Are “Progressing Well”

US Treasury Secretary’s Latest Statement: No Need to Worry About the Deadline for the US-China Suspension of Some Tariff Increases, Negotiations Are “Progressing Well”

金色财经金色财经2025/07/15 21:03
Show original

According to a report by Jinse Finance citing Global Times, U.S. Treasury Secretary Bessent stated in an interview with Bloomberg TV on the 15th local time that the upcoming U.S.-China tariff truce deadline scheduled for next month is flexible, and market participants need not worry about the deadline. The current negotiations between China and the U.S. are “progressing well,” and both sides are expected to hold talks in the coming weeks. “I tell market participants not to worry about the August 12 date,” Bessent said. According to Bloomberg, Bessent was referring to the 90-day deadline for suspending some additional tariffs, which was announced by both sides on May 12. Bessent added that he hopes to meet with the Chinese side as soon as possible, possibly in a third country, with the meeting likely to take place early next month.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar

Deutsche Bank believes that the continuously expanding chip trade surplus in Asia is becoming a supporting force for the US dollar, as related profits are increasingly being reinvested into the US stock market.

智通财经•2026/11/16 23:03
The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar

Roche's (RHHBY.US) new breast cancer drug Wilserdly approved by FDA: Analysts predict peak annual sales could reach up to $14.5 billion

Roche's (RHHBY.US) new oral breast cancer drug has been approved by U.S. regulators, paving the way for this medication, which the pharmaceutical company hopes will transform the treatment of the disease.

智通财经•2026/11/16 22:53